Thus, the use of MLKL antagonists could render the non-toxic HHT doses sufficient for reducing the basal autophagy in CRC cells below the levels required for cell survival and thereby make this combination treatment efficacious against CRC. Here, MLKL is linked to colorectal carcinoma.